Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Infectious Diseases
Published in: BMC Infectious Diseases 1/2012

Open Access 01-12-2012 | Research article

HIV-1 integrase resistance among antiretroviral treatment naive and experienced patients from Northwestern Poland

Authors: Miłosz Parczewski, Dorota Bander, Anna Urbańska, Anna Boroń-Kaczmarska

Published in: BMC Infectious Diseases | Issue 1/2012

Login to get access

Abstract

Background

HIV integrase inhibitor use is limited by low genetic barrier to resistance and possible cross-resistance among representatives of this class of antiretrovirals. The aim of this study was to analyse integrase sequence variability among antiretroviral treatment naive and experienced patients with no prior integrase inhibitor (InI) exposure and investigate development of the InI drug resistance mutations following the virologic failure of the raltegravir containing regimen.

Methods

Sequencing of HIV-1 integrase region from plasma samples of 80 integrase treatment naive patients and serial samples from 12 patients with observed virologic failure on raltegravir containing treatment whenever plasma vireamia exceeded >50 copies/ml was performed. Drug resistance mutations were called with Stanford DB database and grouped into major and minor variants. For subtyping bootstrapped phylogenetic analysis was used; Bayesian Monte Carlo Marcov Chain (MCMC) model was implemented to infer on the phylogenetic relationships between the serial sequences from patients failing on raltegravir.

Results

Majority of the integrase region sequences were classified as subtype B; the remaining ones being subtype D, C, G, as well as CRF01_AE , CRF02_AG and CRF13_cpx recombinants. No major integrase drug resistance mutations have been observed in InI-treatment naive patients. In 30 (38.5%) cases polymorphic variation with predominance of the E157Q mutation was observed. This mutation was more common among subtype B (26 cases, 54.2%) than non-B sequences (5 cases, 16.7%), p=0.00099, OR: 5.91 (95% CI:1.77-22.63)]. Other variants included L68V, L74IL, T97A, E138D, V151I, R263K. Among 12 (26.1%) raltegravir treated patients treatment failure was observed; major InI drug resistance mutations (G140S, Q148H and N155H, V151I, E92EQ, V151I, G163R) were noted in four of these cases (8.3% of the total InI-treated patients). Time to the development of drug resistance ranged from 2.6 to 16.3 months with mean increase of HIV viral load of 4.34 (95% CI:1.86-6.84) log HIV-RNA copies/ml at the time of emergence of the major mutations. Baseline polymorphisms, including E157Q were not associated with the virologic failure on raltegravir.

Conclusions

In InI treatment naive patients polymorphic integrase sequence variation was common, with no major resistance mutants. In the treatment failing patients selection of drug resistance occurred rapidly and followed the typical drug resistance pathways. Preexisting integrase polymorphisms were not associated with the treatment failure.
Appendix
Available only for authorised users
Literature
1.
Steigbigel RT, Cooper DA, Kumar PN, Eron JE, Schechter M, Markowitz M, Loutfy MR, Lennox JL, Gatell JM, Rockstroh JK, et al: Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med. 2008, 359 (4): 339-354. 10.1056/NEJMoa0708975.CrossRefPubMed
2.
Gatell JM: The use of integrase inhibitors in treatment-experienced patients. Eur J Med Res. 2009, 14 (Suppl 3): 30-35.PubMedPubMedCentral
3.
Nguyen BY, Isaacs RD, Teppler H, Leavitt RY, Sklar P, Iwamoto M, Wenning LA, Miller MD, Chen J, Kemp R, et al: Raltegravir: the first HIV-1 integrase strand transfer inhibitor in the HIV armamentarium. Ann N Y Acad Sci. 2011, 1222: 83-89. 10.1111/j.1749-6632.2011.05972.x.CrossRefPubMed
4.
Rockstroh JK, Teppler H, Zhao J, Sklar P, Miller MD, Harvey CM, Strohmaier KM, Leavitt RY, Nguyen BY: Clinical efficacy of raltegravir against B and non-B subtype HIV-1 in phase III clinical studies. AIDS. 2011, 25 (11): 1365-1369. 10.1097/QAD.0b013e328348065a.CrossRefPubMed
5.
Lennox JL, DeJesus E, Lazzarin A, Pollard RB, Madruga JV, Berger DS, Zhao J, Xu X, Williams-Diaz A, Rodgers AJ, et al: Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. Lancet. 2009, 374 (9692): 796-806. 10.1016/S0140-6736(09)60918-1.CrossRefPubMed
6.
Lennox JL, Dejesus E, Berger DS, Lazzarin A, Pollard RB, Ramalho Madruga JV, Zhao J, Wan H, Gilbert CL, Teppler H, et al: Raltegravir versus Efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses. J Acquir Immune Defic Syndr. 2010, 55 (1): 39-48. 10.1097/QAI.0b013e3181da1287.CrossRefPubMed
7.
Correll T, Klibanov OM: Integrase inhibitors: a new treatment option for patients with human immunodeficiency virus infection. Pharmacotherapy. 2008, 28 (1): 90-101. 10.1592/phco.28.1.90.CrossRefPubMed
8.
Grant P, Zolopa A: Integrase inhibitors: a clinical review of raltegravir and elvitegravir. J HIV Ther. 2008, 13 (2): 36-39.PubMed
9.
Hughes A, Barber T, Nelson M: New treatment options for HIV salvage patients: an overview of second generation PIs, NNRTIs, integrase inhibitors and CCR5 antagonists. J Infect. 2008, 57 (1): 1-10. 10.1016/j.jinf.2008.05.006.CrossRefPubMed
10.
Boyd M: Dolutegravir–a promising antiretroviral in development. Lancet Infect Dis. 2012, 12 (2): 90-91. 10.1016/S1473-3099(11)70291-2.CrossRefPubMed
11.
Blanco JL, Martinez-Picado J: HIV integrase inhibitors in ART-experienced patients. Curr Opin HIV AIDS. 2012, 7 (5): 415-421. 10.1097/COH.0b013e328356dcb6.CrossRefPubMed
12.
Cocohoba J, Dong BJ: Raltegravir: the first HIV integrase inhibitor. Clin Ther. 2008, 30 (10): 1747-1765. 10.1016/j.clinthera.2008.10.012.CrossRefPubMed
13.
Cotelle P: Patented HIV-1 integrase inhibitors (1998-2005). Recent Pat Antiinfect Drug Discov. 2006, 1 (1): 1-15.CrossRefPubMed
14.
Miller M: Resistance to integrase inhibitors. J HIV Ther. 2007, 12 (4): 101-PubMed
15.
Cooper DA, Steigbigel RT, Gatell JM, Rockstroh JK, Katlama C, Yeni P, Lazzarin A, Clotet B, Kumar PN, Eron JE, et al: Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N Engl J Med. 2008, 359 (4): 355-365. 10.1056/NEJMoa0708978.CrossRefPubMed
16.
Goethals O, Clayton R, Van Ginderen M, Vereycken I, Wagemans E, Geluykens P, Dockx K, Strijbos R, Smits V, Vos A, et al: Resistance mutations in human immunodeficiency virus type 1 integrase selected with elvitegravir confer reduced susceptibility to a wide range of integrase inhibitors. J Virol. 2008, 82 (21): 10366-10374. 10.1128/JVI.00470-08.CrossRefPubMedPubMedCentral
17.
Malet I, Delelis O, Valantin MA, Montes B, Soulie C, Wirden M, Tchertanov L, Peytavin G, Reynes J, Mouscadet JF, et al: Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro. Antimicrob Agents Chemother. 2008, 52 (4): 1351-1358. 10.1128/AAC.01228-07.CrossRefPubMedPubMedCentral
18.
Roquebert B, Blum L, Collin G, Damond F, Peytavin G, Leleu J, Matheron S, Chene G, Brun-Vezinet F, Descamps D: Selection of the Q148R integrase inhibitor resistance mutation in a failing raltegravir containing regimen. AIDS. 2008, 22 (15): 2045-2046. 10.1097/QAD.0b013e32830f4c7d.CrossRefPubMed
19.
Canducci F, Sampaolo M, Marinozzi MC, Boeri E, Spagnuolo V, Galli A, Castagna A, Lazzarin A, Clementi M, Gianotti N: Dynamic patterns of human immunodeficiency virus type 1 integrase gene evolution in patients failing raltegravir-based salvage therapies. AIDS. 2009, 23 (4): 455-460. 10.1097/QAD.0b013e328323da60.CrossRefPubMed
20.
Ferns RB, Kirk S, Bennett J, Cook PM, Williams I, Edwards S, Pillay D: The dynamics of appearance and disappearance of HIV-1 integrase mutations during and after withdrawal of raltegravir therapy. AIDS. 2009, 23 (16): 2159-2164. 10.1097/QAD.0b013e32832ec4ae.CrossRefPubMed
21.
Canducci F, Marinozzi MC, Sampaolo M, Boeri E, Spagnuolo V, Gianotti N, Castagna A, Paolucci S, Baldanti F, Lazzarin A, et al: Genotypic/phenotypic patterns of HIV-1 integrase resistance to raltegravir. J Antimicrob Chemother. 2010, 65 (3): 425-433. 10.1093/jac/dkp477.CrossRefPubMed
22.
Ceccherini-Silberstein F, Malet I, Fabeni L, Dimonte S, Svicher V, D’Arrigo R, Artese A, Costa G, Bono S, Alcaro S, et al: Specific HIV-1 integrase polymorphisms change their prevalence in untreated versus antiretroviral-treated HIV-1-infected patients, all naive to integrase inhibitors. J Antimicrob Chemother. 2010, 65 (11): 2305-2318. 10.1093/jac/dkq326.CrossRefPubMed
23.
Boyd SD, Maldarelli F, Sereti I, Ouedraogo GL, Rehm CA, Boltz V, Shoemaker D, Pau AK: Transmitted raltegravir resistance in an HIV-1 CRF_AG-infected patient. Antivir Ther. 2011, 16 (2): 257-261. 10.3851/IMP1749.CrossRefPubMedPubMedCentral
24.
Young B, Fransen S, Greenberg KS, Thomas A, Martens S, St Clair M, Petropoulos CJ, Ha B: Transmission of integrase strand-transfer inhibitor multidrug-resistant HIV-1: case report and response to raltegravir-containing antiretroviral therapy. Antivir Ther. 2011, 16 (2): 253-256. 10.3851/IMP1748.CrossRefPubMed
25.
Rhee SY, Liu TF, Kiuchi M, Zioni R, Gifford RJ, Holmes SP, Shafer RW: Natural variation of HIV-1 group M integrase: implications for a new class of antiretroviral inhibitors. Retrovirology. 2008, 5: 74-10.1186/1742-4690-5-74.CrossRefPubMedPubMedCentral
26.
Low A, Prada N, Topper M, Vaida F, Castor D, Mohri H, Hazuda D, Muesing M, Markowitz M: Natural polymorphisms of human immunodeficiency virus type 1 integrase and inherent susceptibilities to a panel of integrase inhibitors. Antimicrob Agents Chemother. 2009, 53 (10): 4275-4282. 10.1128/AAC.00397-09.CrossRefPubMedPubMedCentral
27.
Ceccherini-Silberstein F, Van Baelen K, Armenia D, Trignetti M, Rondelez E, Fabeni L, Scopelliti F, Pollicita M, Van Wesenbeeck L, Van Eygen V, et al: Secondary integrase resistance mutations found in HIV-1 minority quasispecies in integrase therapy-naive patients have little or no effect on susceptibility to integrase inhibitors. Antimicrob Agents Chemother. 2010, 54 (9): 3938-3948. 10.1128/AAC.01720-09.CrossRefPubMedPubMedCentral
28.
Ceccherini-Silberstein F, Malet I, D’Arrigo R, Antinori A, Marcelin AG, Perno CF: Characterization and structural analysis of HIV-1 integrase conservation. AIDS Rev. 2009, 11 (1): 17-29.PubMed
29.
Armenia D, Vandenbroucke I, Fabeni L, Van Marck H, Cento V, D’Arrigo R, Van Wesenbeeck L, Scopelliti F, Micheli V, Bruzzone B, et al: Study of Genotypic and Phenotypic HIV-1 Dynamics of Integrase Mutations During Raltegravir Treatment: A Refined Analysis by Ultra-Deep 454 Pyrosequencing. J Infect Dis. 2012, 205 (4): 557-567. 10.1093/infdis/jir821.CrossRefPubMedPubMedCentral
30.
Fish MQ, Hewer R, Wallis CL, Venter WD, Stevens WS, Papathanasopoulos MA: Natural polymorphisms of integrase among HIV type 1-infected South African patients. AIDS Res Hum Retroviruses. 2010, 26 (4): 489-493. 10.1089/aid.2009.0249.CrossRefPubMed
31.
Garrido C, Geretti AM, Zahonero N, Booth C, Strang A, Soriano V, De Mendoza C: Integrase variability and susceptibility to HIV integrase inhibitors: impact of subtypes, antiretroviral experience and duration of HIV infection. J Antimicrob Chemother. 2010, 65 (2): 320-326. 10.1093/jac/dkp423.CrossRefPubMed
32.
Charpentier C, Laureillard D, Piketty C, Tisserand P, Batisse D, Karmochkine M, Si-Mohamed A, Weiss L: High frequency of integrase Q148R minority variants in HIV-infected patients naive of integrase inhibitors. AIDS. 2010, 24 (6): 867-873. 10.1097/QAD.0b013e3283367796.CrossRefPubMed
33.
Vandamme AM, Camacho RJ, Ceccherini-Silberstein F, de Luca A, Palmisano L, Paraskevis D, Paredes R, Poljak M, Schmit JC, Soriano V, et al: European recommendations for the clinical use of HIV drug resistance testing: 2011 update. AIDS Rev. 2011, 13 (2): 77-108.PubMed
34.
Van Laethem K, Schrooten Y, Covens K, Dekeersmaeker N, De Munter P, Van Wijngaerden E, Van Ranst M, Vandamme AM: A genotypic assay for the amplification and sequencing of integrase from diverse HIV-1 group M subtypes. J Virol Methods. 2008, 153 (2): 176-181. 10.1016/j.jviromet.2008.07.008.CrossRefPubMed
35.
Harrigan PR DW, Wynhoven B, Mo T, Hall T, Galli R: XIV International AIDS Conference, Spain, Barcelona Abstract #TuPeB4598. The Performance of ReCall basecalling software for high-throughput HIV drug resistance basecalling using “in-house” methods. 2002
36.
37.
Guindon S, Dufayard JF, Lefort V, Anisimova M, Hordijk W, Gascuel O: New algorithms and methods to estimate maximum-likelihood phylogenies: assessing the performance of PhyML 3.0. Syst Biol. 2010, 59 (3): 307-321. 10.1093/sysbio/syq010.CrossRefPubMed
38.
Posada D: jModelTest: phylogenetic model averaging. Mol Biol Evol. 2008, 25 (7): 1253-1256. 10.1093/molbev/msn083.CrossRefPubMed
39.
40.
Tseng A, Foisy M: Important Drug-Drug Interactions in HIV-Infected Persons on Antiretroviral Therapy: An Update on New Interactions Between HIV and Non-HIV Drugs. Curr Infect Dis Rep. 2012, 14 (1): 67-82. 10.1007/s11908-011-0229-1.CrossRefPubMed
41.
Lampiris HW: Elvitegravir: a once-daily, boosted, HIV-1 integrase inhibitor. Expert Rev Anti Infect Ther. 2012, 10 (1): 13-20. 10.1586/eri.11.157.CrossRefPubMed
42.
Katlama C, Murphy R: Dolutegravir for the treatment of HIV. Expert Opin Investig Drugs. 2012, 21 (4): 523-530. 10.1517/13543784.2012.661713.CrossRefPubMed
43.
44.
Powderly WG: Integrase inhibitors in the treatment of HIV-1 infection. J Antimicrob Chemother. 2010, 65 (12): 2485-2488. 10.1093/jac/dkq350.CrossRefPubMed
45.
Gatell JM, Katlama C, Grinsztejn B, Eron JJ, Lazzarin A, Vittecoq D, Gonzalez CJ, Danovich RM, Wan H, Zhao J, et al: Long-term efficacy and safety of the HIV integrase inhibitor raltegravir in patients with limited treatment options in a Phase II study. J Acquir Immune Defic Syndr. 2010, 53 (4): 456-463. 10.1097/QAI.0b013e3181c9c967.CrossRefPubMed
46.
Turriziani O, Montagna C, Falasca F, Bucci M, Russo G, Lichtner M, Sobze MS, Vullo V, Pistello M, Antonelli G: Analysis of the Integrase Gene from HIV Type 1-Positive Patients Living in a Rural Area of West Cameroon. AIDS Res Hum Retroviruses. 2012, 28 (12): 1729-1733. 10.1089/aid.2011.0266.CrossRefPubMed
47.
Oliveira MF, Ramalho DB, Abreu CM, Vubil A, Mabunda N, Ismael N, Francisco C, Jani IV, Tanuri A: Genetic Diversity and Naturally Polymorphisms in HIV Type 1 Integrase Isolates from Maputo, Mozambique: Implications for Integrase Inhibitors. AIDS Res Hum Retroviruses. 2012, 28 (12): 1788-1792. 10.1089/aid.2012.0058.CrossRefPubMedPubMedCentral
48.
Nouhin J, Donchai T, Hoang KT, Ken S, Kamkorn J, Tran T, Ayouba A, Peeters M, Chaix ML, Lien TX, et al: Natural polymorphisms of HIV-1 CRF01_AE integrase coding region in ARV-naive individuals in Cambodia, Thailand and Vietnam: an ANRS AC12 working group study. Infect Genet Evol. 2011, 11 (1): 38-43. 10.1016/j.meegid.2010.10.014.CrossRefPubMed
49.
Kumar A, Jadhav C: Genotypic prediction of resistant mutation in HIV-1 pol gene towards the antiretroviral drugs. Int J Bioinform Res Appl. 2011, 7 (1): 15-23. 10.1504/IJBRA.2011.039167.CrossRefPubMed
50.
Varghese V, Liu TF, Rhee SY, Libiran P, Trevino C, Fessel WJ, Shafer RW: HIV-1 integrase sequence variability in antiretroviral naive patients and in triple-class experienced patients subsequently treated with raltegravir. AIDS Res Hum Retroviruses. 2010, 26 (12): 1323-1326. 10.1089/aid.2010.0123.CrossRefPubMedPubMedCentral
51.
Goethals O, Vos A, Van Ginderen M, Geluykens P, Smits V, Schols D, Hertogs K, Clayton R: Primary mutations selected in vitro with raltegravir confer large fold changes in susceptibility to first-generation integrase inhibitors, but minor fold changes to inhibitors with second-generation resistance profiles. Virology. 2010, 402 (2): 338-346. 10.1016/j.virol.2010.03.034.CrossRefPubMed
52.
Reuman EC, Bachmann MH, Varghese V, Fessel WJ, Shafer RW: Panel of prototypical raltegravir-resistant infectious molecular clones in a novel integrase-deleted cloning vector. Antimicrob Agents Chemother. 2010, 54 (2): 934-936. 10.1128/AAC.01345-09.CrossRefPubMed
53.
Saladini F, Meini G, Bianco C, Monno L, Punzi G, Pecorari M, Borghi V, Di Pietro M, Filice G, Gismondo MR, et al: Prevalence of HIV-1 integrase mutations related to resistance to dolutegravir in raltegravir naive and pretreated patients. Clin Microbiol Infect. 2012, 18 (10): E428-E430. 10.1111/j.1469-0691.2012.03917.x.CrossRefPubMed
54.
Monleau M, Aghokeng AF, Nkano BA, Chaix ML, Peeters M: Drug resistance mutations of HIV-1 non-B viruses to integrase inhibitors in treatment-naive patients from sub-Saharan countries and discordant interpretations. AIDS Res Hum Retroviruses. 2012, 28 (29): 1157-1160.PubMed
55.
Mantovani NP, Azevedo RG, Rabelato JT, Sanabani S, Diaz RS, Komninakis SV: Analysis of Transmitted Resistance to Raltegravir and Selective Pressure among HIV-1-Infected Patients on a Failing HAART in Sao Paulo, Brazil. J Clin Microbiol. 2012, 50 (6): 2122-2125. 10.1128/JCM.00539-12.CrossRefPubMedPubMedCentral
56.
Luu QP, Dean J, Do TT, Carr MJ, Dunford L, Coughlan S, Connell J, Hien NT WWH, Nguyen Thi LA: HIV-1 Coreceptor Tropism, CCR5 Genotype and Integrase Inhibitor Resistance Profiles in Vietnam - Implications for the Introduction of New Antiretroviral Regimens. AIDS Res Hum Retroviruses. 2012, 28 (10): 1344-1348. 10.1089/aid.2011.0396.CrossRefPubMed
57.
Winslow DL: Resistance to HIV integrase inhibitors. AIDS Alert. 2011, 26 (9): 106-107.PubMed
58.
Phuphuakrat A, Pasomsub E, Kiertiburanakul S, Chantratita W, Sungkanuparph S: HIV Type 1 Integrase Polymorphisms in Treatment-Naive and Treatment-Experienced HIV Type 1-Infected Patients in Thailand Where HIV Type 1 Subtype A/E Predominates. AIDS Res Hum Retroviruses. 2011, 28 (8): 937-943.CrossRefPubMed
59.
Rangel HR, Garzaro D, Fabbro R, Martinez N, Ossenkop J, Torres JR, Gutierrez CR, Pujol FH: Absence of primary integrase resistance mutations in HIV type 1-infected patients in Venezuela. AIDS Res Hum Retroviruses. 2010, 26 (8): 923-926. 10.1089/aid.2010.0039.CrossRefPubMed
60.
van Hal SJ, Herring B, Deris Z, Wang B, Saksena NK, Dwyer DE: HIV-1 integrase polymorphisms are associated with prior antiretroviral drug exposure. Retrovirology. 2009, 6: 12-10.1186/1742-4690-6-12.CrossRefPubMedPubMedCentral
61.
Charpentier C, Karmochkine M, Laureillard D, Tisserand P, Belec L, Weiss L, Si-Mohamed A, Piketty C: Drug resistance profiles for the HIV integrase gene in patients failing raltegravir salvage therapy. HIV Med. 2008, 9 (9): 765-770. 10.1111/j.1468-1293.2008.00628.x.CrossRefPubMed
62.
Kobayashi M, Nakahara K, Seki T, Miki S, Kawauchi S, Suyama A, Wakasa-Morimoto C, Kodama M, Endoh T, Oosugi E, et al: Selection of diverse and clinically relevant integrase inhibitor-resistant human immunodeficiency virus type 1 mutants. Antiviral Res. 2008, 80 (2): 213-222. 10.1016/j.antiviral.2008.06.012.CrossRefPubMed
63.
da Silva D, Van Wesenbeeck L, Breilh D, Reigadas S, Anies G, Van Baelen K, Morlat P, Neau D, Dupon M, Wittkop L, et al: HIV-1 resistance patterns to integrase inhibitors in antiretroviral-experienced patients with virological failure on raltegravir-containing regimens. J Antimicrob Chemother. 2010, 65 (6): 1262-1269. 10.1093/jac/dkq099.CrossRefPubMed
64.
Vavro C, Dudas K, Hasan S, Huang J, Yeo Y, Underwood M: “International Workshop on HIV & Hepatitis Virus Drug Resistance and Curative Strategies; June 5-9, 2012; Sitges, Spain”, Abstract 3. Dolutegravir Treatment of HIV Subjects With Raltegravir Resistance: Integrase Resistance Evolution in Cohort II of the VIKING Study. 2012
65.
Blanco JL, Varghese V, Rhee SY, Gatell JM, Shafer RW: HIV-1 Integrase Inhibitor Resistance and Its Clinical Implications. J Infect Dis. 2011, 203 (9): 1204-1214. 10.1093/infdis/jir025.CrossRefPubMedPubMedCentral
66.
Fransen S, Gupta S, Frantzell A, Petropoulos CJ, Huang W: Substitutions at Amino Acid Positions 143, 148 and 155 of HIV-1 Integrase Define Distinct Genetic Barriers to Raltegravir Resistance in vivo. J Virol. 2012, 86 (13): 7249-7255. 10.1128/JVI.06618-11.CrossRefPubMedPubMedCentral
67.
Hu Z, Kuritzkes DR: Effect of raltegravir resistance mutations in HIV-1 integrase on viral fitness. J Acquir Immune Defic Syndr. 2010, 55 (2): 148-155. 10.1097/QAI.0b013e3181e9a87a.CrossRefPubMedPubMedCentral
68.
Hatano H, Lampiris H, Fransen S, Gupta S, Huang W, Hoh R, Martin JN, Lalezari J, Bangsberg D, Petropoulos C, et al: Evolution of integrase resistance during failure of integrase inhibitor-based antiretroviral therapy. J Acquir Immune Defic Syndr. 2010, 54 (4): 389-393.CrossRefPubMedPubMedCentral
Metadata
Title
HIV-1 integrase resistance among antiretroviral treatment naive and experienced patients from Northwestern Poland
Authors
Miłosz Parczewski
Dorota Bander
Anna Urbańska
Anna Boroń-Kaczmarska
Publication date
01-12-2012
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2012
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/1471-2334-12-368

Other articles of this Issue 1/2012

BMC Infectious Diseases 1/2012 Go to the issue

Research article

The community impact of the 2009 influenza pandemic in the WHO European Region: a comparison with historical seasonal data from 28 countries

Research article

Residential crowding and severe respiratory syncytial virus disease among infants and young children: A systematic literature review

Research article

The risk of AIDS-defining events is decreasing over time in the German HIV-1 Seroconverter Cohort

Research article

Predictors of the development of myocarditis or acute renal failure in patients with leptospirosis: An observational study

Research article

Escherichia coli–expressed near full length HIV-1 envelope glycoprotein is a highly sensitive and specific diagnostic antigen

Research article

Modeling the impact of air, sea, and land travel restrictions supplemented by other interventions on the emergence of a new influenza pandemic virus
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits